Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ALS and acquired Mexico City-based ARJ
  • ARJ is the largest, private pharmaceutical testing lab in Latin America
  • Mexico is a growing contributor to the $20 billion global pharmaceutical testing market and an important hub for Latin and North America
  • ALS states the acquisition of ARJ supports its strategy focusing on food and pharmaceutical opportunities in key growth markets such as Latin America

Brisbane-based ALS has acquired Laboratorios de Control ARJ (ARJ).

ALS is a leading testing, inspection, certification and verification company trying to expand its global presence.

Based in Mexico City, ARJ is the largest, private pharmaceutical testing lab in Latin America with revenues of over $30 million.

ARJ was founded in 1967 and has steadily grown its business, employing over 500 people. It specialises in providing quality control for medicines, biological products, generics, biosimilars, cosmetics and medical devices. It also services many of the world’s largest pharmaceutical companies.

Mexico is a growing contributor to the $20 billion global pharmaceutical testing market and an important hub for Latin and North America.

“ARJ has a world class operation and client base which offers us a strong platform to continue to grow our presence in key markets including Argentina, Brazil, Colombia, and Mexico. We welcome the ARJ team to ALS and look forward to our collaboration with them throughout the region,” ALS Managing Director and CEO Raj Naran said.

ALS’ acquisition of ARJ is supported by the company’s existing Life Sciences Latin America operations and is expected to benefit from Group’s regional and global presence to further expand their offerings to clients.

“The acquisition of ARJ aligns with our stated acquisition strategy focusing on food and pharmaceutical opportunities in key growth markets such as Latin America,” Raj said.

ALQ by the numbers
More From The Market Herald
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.

" Paragon Care (ASX:PGC) enters partnership with Centuria Healthcare for a healthcare facility

Paragon Care (PGC) has entered into a partnership with Centuria Healthcare for the 15-year lease of a state-of-the-art healthcare facility in Melbourne.